secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2022-06-01T23:59:59+00:00
Accession:  0000950170-22-011025
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharmaceuticals appoints Kerry Russell as Chief Medical Officer effective June 1, 2022
--------------------------------------------------------------------------------

- Kerry Russell, M.D., Ph.D., named CMO, reporting to President and Head of R&D Erin Quirk, M.D.
- Dr. Russell previously VP of late clinical development at Dicerna Pharmaceuticals (acquired by Novo Nordisk).
- She held leadership roles at resTORbio, Novartis, and was an NIH-funded associate professor at Yale.
- Terns expects key clinical data readouts for TERN-501, TERN-601, and TERN-701 across NASH, obesity, and CML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017022011025/0000950170-22-011025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017022011025/tern-20220601.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer